Katsuyama A, et al. - Researchers estimated the long-term effectiveness and tolerability of infliximab (IFX) and cyclosporine (CsA) combination therapy for the treatment of refractory uveoretinitis in Behcet’s disease (BD) cases. They noted a marked decline in the frequency of ocular attacks per 6-month period from 2.9±1.6 during the baseline period to 0.6±0.9 during months 1–6, 0.5±0.9 during months 7–12, 0.3±0.5 during months 13–18, 0.3±0.7 during months 19–24, and 0.0±0.0 thereafter. A significant decrease from 5.2±2.4 during the baseline period to 1.5±2.1 during months 1–6, 1.7±3.1 during months 7–12, 1.6±2.9 during months 13–18, and 0.4±1.0 during months 19–24 in the Behcet’s disease ocular attack score 24 (BOS24) per ocular attack was also reported. Except for urinary tract infection and cataract progression, they did not observe any serious adverse effect. Hence, they recommended IFX+CsA combination therapy to reduce the frequency and severity of ocular inflammatory attacks in the long-term.